Life-2023-02 Esophagogastric Variceal Bleeding

Study Overview
=================
Brief Summary
-----------------
Study on the efficacy of the growth inhibitors after endoscopic treatment of acute esophagogastric variceal bleeding

Detailed Description
-----------------
Participants with acute esophagogastric variceal bleeding in 5 days and under stable status will be included in this study. All the patients will take CTP test to confirm the blood flow status of the portal vein before endoscopic treatment. After that they will be randomly divided into two groups: A. accept growth inhibitors after the endoscopic treatment for 5 days; B. no growth inhibitor will be applied after the treatment.

Official Title
-----------------
Life-2023-02 Study on the Efficacy of Growth Inhibitors After Endoscopic Treatment of Acute Esophagogastric Variceal Bleeding

Conditions
-----------------
Acute Esophageal Variceal Hemorrhage

Intervention / Treatment
-----------------
* Drug: Growth Inhibitor


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: acute esophagogastric bleeding with hepatic cirhosis; stable status (no active bleeding) Exclusion Criteria: endoscopic test limitation; previous acute esophagogastric bleeding treatment history; ICU; pregnant; Immunity disabled;

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Group A<br>Participants in this group will take growth inhibitors for 5 days after endoscopic treatment. | Drug: Growth Inhibitor<br>* growth inhibitors for 250-500μg/h, ivgtt. for 5 days<br>|
| No Intervention: Group B<br>Participants in this group will not take growth inhibitor treatment after endoscopic treatment. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| rebleeding rate after the endoscopic treatment in Group A at 1 month | record the rebleeding incidence in this group A; (Rate A1= the number of rebleeding participants/the number of all the participants) | 1 month after the endoscopic treatment | 
| rebleeding rate after the endoscopic treatment in Group A at 3 months | record the rebleeding incidence in this group A; (Rate A2= the number of rebleeding participants/the number of all the participants) | 3 months after the endoscopic treatment | 
| rebleeding rate after the endoscopic treatment in Group A at 6 months | record the rebleeding incidence in this group A; (Rate A3= the number of rebleeding participants/the number of all the participants) | 6 months after the endoscopic treatment | 
| rebleeding rate after the endoscopic treatment in Group B at 1 month | record the rebleeding incidence in this group B; (Rate B1= the number of rebleeding participants/the number of all the participants) | 1 month after the endoscopic treatment | 
| rebleeding rate after the endoscopic treatment in Group B at 3 months | record the rebleeding incidence in this group B; (Rate B2= the number of rebleeding participants/the number of all the participants) | 3 months after the endoscopic treatment | 
| rebleeding rate after the endoscopic treatment in Group B at 6 months | record the rebleeding incidence in this group B; (Rate B3= the number of rebleeding participants/the number of all the participants) | 6 months after the endoscopic treatment |